Drug Tracker: CE rejection rate problematic for pricing
The latest Drug Tracker analysis of PBAC outcomes shows that an increasing rejection rate for major cost-effectiveness submissions may have potential to affect return on investment for new drugs and indications

Roche reacts to changing pharma environment
Roche has wasted no time in reacting to a series of delays and disappointments that have affected its business over recent months and to changing pressures in the world of drug funding